Immunohistochemical expression of integrins and extracellular matrix proteins in non-small cell lung cancer: Correlation with lymph node metastasis

Lung Cancer

Volumn 41, Issue 1, 2003, Pages 65-70

  Han, Ji Youn ^a   Kim, Hong Sug ^b   Lee, Sug Hyung ^b   Park, Won Sang ^b   Lee, Jung Young ^b   Yoo, Nam Jin ^b  

^a National Cancer Center   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Collagen; Extracellular matrix; Fibronectin; Integrins; Non small cell lung cancer; Tenascin

Indexed keywords

ALPHA2 INTEGRIN; ALPHA3 INTEGRIN; ALPHA4 INTEGRIN; ALPHA5 INTEGRIN; BETA1 INTEGRIN; COLLAGEN TYPE 4; FIBRONECTIN; INTEGRIN; SCLEROPROTEIN; TENASCIN; UNCLASSIFIED DRUG;

ARTICLE; CELL INVASION; CELL SURVIVAL; CHI SQUARE TEST; CORRELATION ANALYSIS; EXTRACELLULAR MATRIX; FISHER EXACT TEST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR CELL;

EID: 0038798482     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00146-6     Document Type: Article

References (25)

1. Annual Report on the Cause of Death Statistics. Korean Government, 2002.
2. Zochbauer-Muller S., Gazdar A.F., Minna J.D. Molecular pathogenesis of lung cancer. Annu. Rev. Physiol. 64:2002;681-708.
3. Bunn P.A. Jr., Mault J., Kelly K. Adjuvant and neoadjuvant chemotherapy for non-small cell lung cancer: a time for reassessment? Chest. 117:(4, Suppl. 1):2000;119S-122S.
4. Vansteenkiste J.F., De Leyn P.R., Deneffe G.J., Lerut T.E., Demedts M.G. Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: analysis of the literature. Lung Cancer. 19:1998;3-13.
5. Andre F., Grunenwald D., Pignon J.P., et al. Survival of patients with resected N2 non-small cell lung cancer: evidence for a subclassification and implications. J. Clin. Oncol. 18:2000;2981-2989.
6. Engers R., Gabbert H.E., et al. Mechanisms of tumor metastasis: cell biological aspects and clinical implications. J. Cancer Res. Clin. Oncol. 126:2000;682-692.
7. Holly S.P., Larson M.K., Parise L.V. Multiple roles of integrins in cell motility. Exp. Cell Res. 261:2000;69-74.
8. Brakebusch C., Bouvard D., Stanchi F., Sakai T., Fassler R. Integrins in invasive growth. J. Clin. Invest. 109:2002;999-1006.
9. Giancotti F.G., Ruoslahti E. Integrin signaling. Science. 285:1999;1028-1032.
10. Zhang Z., Vuori K., Reed J.C., Ruoslahti E. The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc. Natl. Acad. Sci. USA. 92:1995;6161-6165.
11. Huttenlocher A., Lakonishok M., Kinder M., et al. Integrin and cadherin synergy regulates contact inhibition of migration and motile activity. J. Cell Biol. 141:1998;515-526.
12. Takenaka K., Shibuya M., Takeda Y., et al. Altered expression and function of beta 1 integrins in a highly metastatic human lung adenocarcinoma cell line. Int. J. Oncol. 17:2000;1187-1194.
13. Bartolazzi A., Cerboni C., Flamini G., Bigotti A., Lauriola L., Natali P.G. Expression of alpha 3 beta 1 integrin receptor and its ligands in human lung tumors. Int. J. Cancer. 64:1995;248-252.
14. Oshita F., Kameda Y., Ikehara M., et al. Increased expression of integrin beta1 is a poor prognostic factor in small-cell lung cancer. Anticancer Res. 22:2002;1065-1070.
15. Adachi M., Taki T., Higashiyama M., Kohno N., Inufusa H., Miyake M. Significance of integrin alpha 5 gene expression as a prognostic factor in node-negative non-small cell lung cancer. Clin. Cancer Res. 6:2000;96-101.
16. Clarke M.R., Landreneau R.J., Finkelstein S.D., Wu T.T., Ohori P., Yousem S.A. Extracellular matrix expression in metastasizing and nonmetastasizing adenocarcinomas of the lung. Hum. Pathol. 28:1997;54-59.
17. Liotta L.A., Rao C.N., Barsky S.H. Tumor invasion and the extracellular matrix. Lab. Invest. 49:1983;636-649.
18. Liotta L.A. Tumor invasion and metastases: role of the basement membrane. Warner-Lambert Parke-Davis Award lecture. Am. J. Pathol. 117:1984;339-348.
19. D'Ardenne A.J., Burns J., Sykes B.C., Kirkpatrick P. Comparative distribution of fibronectin and type III collagen in normal human tissues. J. Pathol. 141:1983;55-69.
20. Chiquet M., Fambrough D.M. Chick myotendinous antigen. I. A monoclonal antibody as a marker for tendon and muscle morphogenesis. J. Cell Biol. 98:1984;1926-1936.
21. Ishihara A., Yoshida T., Tamaki H., Sakakura T. Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin. Cancer Res. 1:1995;1035-1041.
22. Giancotti F.G., Ruoslahti E. Elevated levels of the alpha 5 beta 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell. 60:1990;849-859.
23. Danen E.H., Ten Berge P.J., Van Muijen G.N., Van't Hof-Grootenboer A.E., Brocker E.B., Ruiter D.J. Emergence of alpha 5 beta 1 fibronectin- and alpha 5 beta 3 vitronectin-receptor expression in melanocytic tumor progression. Histopathology. 24:1994;249-256.
24. Terol M.J., Lopez-Guillermo A., Bosch F., et al. Expression of beta-integrin adhesion molecules in non-Hodgkin's lymphoma: correlation with clinical and evolutive features. J. Clin. Oncol. 17:1999;1869-1875.
25. Pazdur R., Coia L.R., Hoskins W.J., et al. Cancer Management: A Multidisciplinary Approach. 6th ed. 2002;PRR, Melville.